Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462559) titled 'KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study' on March 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Helsinki University Central Hospital
Condition:
Drug Drug Interaction
Intervention:
Drug: Ketamine 10 mg/ml oral solution, UK special
Drug: Cobisistat Tybost 150 mg
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 4, 2026
Target Sample Size: 12
Countries of Recruitment:
Finland
To know more, visit https:/...